#United States #Menlo Park #MyOme #CASRcade #ADH1

MyOme Introduces CASRcade: A Revolutionary Free Genetic Testing Program

In recent news, MyOme has officially launched a groundbreaking initiative called CASRcade, designed to support families impacted by Autosomal Dominant Hypocalcemia Type 1 (ADH1). This innovative program is sponsored by BridgeBio and aims to offer free cascade genetic testing to the biological relatives of individuals diagnosed with this rare genetic condition.

ADH1 is a genetic form of hypoparathyroidism stemming from variants in the calcium-sensing receptor gene (CASR). Those affected by ADH1 face numerous challenges, and MyOme is stepping in to bridge the gap in genetic testing availability. With CASRcade, families can benefit from no-cost familial variant testing and comprehensive genetic counseling, encouraging proactive health management for individuals potentially at risk of inheriting the condition.

Understanding ADH1 and Genetic Inheritance

ADH1 results from gain-of-function variants in the CASR gene, which plays a crucial role in the regulation of parathyroid hormone secretion and calcium levels in the body. The inheritance pattern of ADH1 is autosomal dominant, meaning each child of an affected parent has a 50% chance of inheriting the variant. Unfortunately, identifying other at-risk relatives often proves challenging, leaving many unaware of their potential genetic predisposition.

Dr. Akash Kumar, the Chief Medical Officer at MyOme, states, "Genetic conditions often affect entire families, yet identifying at-risk relatives can be challenging. By expanding access to family cascade genetic testing, we can help more individuals understand whether they carry the same CASR genetic variant and, when appropriate, take informed steps toward proactive care." This statement underscores the mission behind CASRcade: to enhance awareness and initiate earlier diagnoses for affected families.

The CASRcade Program

The CASRcade program simplifies the process for families to engage in genetic testing. Participating healthcare providers can enroll patients diagnosed with ADH1 through MyOme. After enrolling, patients have the opportunity to identify biological relatives who might qualify for the family cascade genetic testing. MyOme then undertakes targeted genetic sequencing to ascertain whether enrolled relatives carry the same CASR variant found in the family.

This cascading process can extend the testing to other family members, allowing for a more comprehensive understanding of genetic risks within the family unit. Positive results not only facilitate immediate genetic discussions but also allow cousin or sibling testing to continue the cascade, ensuring the entire family can gain insights into their health.

Additionally, those who receive a positive result will have access to genetic counseling through certified third-party providers. This service aims to support families navigating the complexities of genetic health, providing clarity and guidance in understanding their test results and potential next steps.

The Importance of Genetic Counseling

With the complexities surrounding genetic testing, access to genetic counseling becomes crucial. For families affected by a genetic disorder like ADH1, being well-informed about their options and the implications of their results is vital. Genetic counselors can help families process the information received, discuss the emotional aspects, and plan for future health care needs.

About MyOme

Founded in Menlo Park, California, MyOme specializes in clinical whole-genome analysis, intended to empower individuals with insights about their health risks. Leveraging both genome sequencing and advanced AI analytics, the company seeks to enhance disease risk assessment and health planning through its innovative platform. MyOme's commitment to improving patient outcomes while reducing healthcare costs positions it at the forefront of genetic testing technology.

As they embark on this significant journey with CASRcade, MyOme is not just expanding their offerings but also providing a necessary resource for families facing the challenges of Autosomal Dominant Hypocalcemia Type 1. Through this initiative, the hope is to ultimately foster a wider understanding of genetic health and prompt families toward timely diagnosis and care.